|
健保碼及健保價 |
|
See related Aggrastat infusion conc[雅瑞 濃縮輸注液] information |
|
|
|
製造商 |
Invida |
|
代理/經銷商 |
Invida |
|
成份 |
Tirofiban HCl |
|
適應症 |
Used in combination with heparin for patients with unstable angina or non-Q-wave MI to prevent cardiac ischemic events & is also for patients with coronary ischemic syndromes undergoing coronary angioplasty or atherectomy to prevent cardiac ischemic complications related to abrupt closure of the treated coronary artery. |
|
用量 |
Dilute Aggrastat prior to administration to achieve a concentration of 50 mcg/mL. Unstable angina pectoris or non-Q-wave MI Initial infusion rate: 0.4 mcg/kg/min for 30 mins. Maintenance infusion rate: 0.1 mcg/kg/min. Angioplasty/atherectomy Initial bolus: 10 mcg/kg over 3 mins. Maintenance infusion rate: 0.15 mcg/kg/min for 36 hr. Severe renal insufficiency Reduce dose by 50%. |
|
過量 |
View Aggrastat[雅瑞] overdosage for action to be taken in the event of an overdose. |
|
美國食品藥物管理局之懷孕等級 |
Category B: Either animal-reproduction studies have not demonstrated a foetal risk but there are no controlled studies in pregnant women or animal-reproduction studies have shown an adverse effect (other than a decrease in fertility) that was not confirmed in controlled studies in women in the 1st trimester (and there is no evidence of a risk in later trimesters). |
|
禁忌 |
Active internal bleeding; a history of intracranial hemorrhage; intracranial neoplasm, arteriovenous malformation or aneurysm; patients who developed thrombocytopenia following prior exposure to Aggrastat. |
|
注意事項 |
Recent (< 1 year) bleeding, including a history of GI bleeding or genitourinary bleeding of clinical significance; known coagulopathy, platelet disorder or history of thrombocytopenia; platelet count < 150,000 cells/mm3; history of cerebrovascular disease within 1 year; major surgical procedure or severe physical trauma within 1 month; recent epidural procedure; history, symptoms or findings suggestive of aortic dissection; severe uncontrolled HTN (systolic BP > 180 mmHg &/or diastolic BP > 110 mmHg); acute pericarditis; hemorrhagic retinopathy; arterial access for femoral sheath placement; chronic hemodialysis; severe renal insufficiency (CrCl < 30 mL/min). Pregnancy, lactation, children. |
|
不良反應 |
Risk of bleeding; nausea; fever; headache.
View ADR Monitoring Website[參閱藥物不良反應監測表格] |
|
副作用 |
View Aggrastat[雅瑞] side effects |
|
交互作用 |
Drugs that affect hemostasis (eg warfarin).
View more drug interactions with Aggrastat[雅瑞] |
|
儲存 |
View Aggrastat[雅瑞] storage conditions for details to ensure optimal shelf-life. |
|
作用 |
View Aggrastat[雅瑞] mechanism of action for pharmacodynamics and pharmacokinetics details. |
|
本商品之市售規格 |
|
劑型 |
包裝 |
圖片 |
|
Aggrastat 濃縮注射劑 |
|
Aggrastat 0.25 mg/1 mL x 50 mL |
|
|
|
Manufacturer: |
Invida |
|
Distributor: |
Invida |
|
|
|
|
